Cypherpunk Technologies Inc. (CYPH)
CYPH trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2021-12-31, https://www.sec.gov/Archives/edgar/data/1509745/000110465923036239/0001104659-23-036239-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2021-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CYPH on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001509745 |
| SEC industry code | Finance Services |
| Incorporated in | DE |
Financials · 2021
| Line | Value |
|---|---|
| Revenue | $1.5M |
| Net income | -$40.6M |
| Operating income | -$41.4M |
| Net margin | -2705.8% |
| Operating margin | -2761.7% |
| Revenue growth | 0.0% |
| Cash | $114.9M |
| Total assets | $117.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 138.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "In accordance with Accounting Standards Codification ( ASC ) 205-40, Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued." | 10-Q 2026-08-12 |
| Cash and burn | $7.6M cash; operating cash flow -$5.3M a quarter. | Report 2026-06-30 |
| Shares outstanding | 107,764,382 (2026-08-10); 41,439,529 a year earlier; 25,565,414 three years earlier. | Cover page 2026-08-10 |
| Reverse splits, 3 years | 2; latest on 2025-12-16 | Source 2025-12-16 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-07-21 |
| Auditor | EisnerAmper LLP, Philadelphia, Pennsylvania, United States | PCAOB Form AP 2026-03-16 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $3.1M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | $39.4M | -$2.7M | $7.6M | No debt tags | Needs four quarters | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | Not filed | -$77.2M | -$3.4M | $6.7M | No debt tags | Needs four quarters | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | Not filed | $40.2M | -$6.6M | $14.0M | No debt tags | Needs four quarters | 10-K 2026-03-16 |
| Q3 2025 2025-09-30 | Not filed | -$3.3M | -$8.3M | $9.7M | No debt tags | Needs four quarters | 10-Q 2025-11-12 |
| Q2 2025 2025-06-30 | Not filed | -$16.6M | -$14.5M | $18.1M | No debt tags | Needs four quarters | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | Not filed | -$15.4M | -$14.5M | $32.7M | No debt tags | Needs four quarters | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | Not filed | -$15.4M | -$15.5M | $47.2M | No debt tags | Needs four quarters | 10-K 2026-03-16 |
| Q3 2024 2024-09-30 | Not filed | -$18.2M | -$15.6M | $62.8M | No debt tags | Needs four quarters | 10-Q 2025-11-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-11-12 |
| Latest annual report | 10-K | 2026-03-16 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report FORM 8-K | 8-K | 2026-11-16 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 625 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -35.1% |
| 1 month | -34.2% |
| 3 months | +188.6% |
| Year to date | +61.2% |
| 1 year | +6.3% |
| From 52-week high | -54.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SIGA | SIGA Technologies Inc. | $2.85 | +4.01% | $204.8M |
| YARW | Yarrow Bioscience Inc. | $13.93 | -22.74% | $212.2M |
| ACIU | AC Immune SA | $2.09 | -1.88% | $212.7M |
| GLSI | Greenwich LifeSciences Inc. | $13.76 | -7.90% | $202.0M |
| VOGX | Vogenx Inc | $14.38 | -13.74% | $213.6M |
| KROS | Keros Therapeutics Inc. | $10.03 | -2.62% | $196.8M |
| NGEN | NervGen Pharma Corp. | $1.82 | -3.19% | $195.9M |
| TRDA | Entrada Therapeutics Inc. | $5.00 | -1.77% | $195.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier